Apotex ships Canada's first drugs under TRIPS
This article was originally published in Scrip
The Canadian company Apotexhas shipped seven million tablets of its HIV/AIDS triple combination drug Apo-TriAvir (zidovudine, lamivudine plus nevirapine) to treat up to 21,000 people in Rwanda. The shipment, which took place on September 24th from Toronto, was approved under Canada's Access to Medicines Regime (CAMR), which was established in May 2004 to allow Canadian generic drug makers to produce patented drugs legally and to export them to developing countries using flexibilities in the World Trade Organization's TRIPS agreement. However, the CAMR process is complicated, and Apotex is the only company since its 2004 launch to have submitted a proposal and negotiated the CAMR process, receiving official approval in May (Scrip Online, May 9th, 2008). Apotex president Jack Kay described the process as "complex" and said "the regime must be changed… It is now up to the federal government to fix CAMR." Apotex is expected to provide a second shipment of seven million doses of Apo-TriAvir in September 2009. The company is completing the work on a humanitarian, not-for-profit basis.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).